Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Product Type
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Explore how neutrophils shape the immune response in health and disease. This poster highlights neutrophil pathogen defense mechanisms, including phagocytosis, degranulation, and NETosis, as well as neutrophil roles in inflammation and NET-associated pathologies.
DOWNLOAD NOWBM212 is an antimycobacterial compound.1 It inhibits the growth of laboratory and clinical isolate M. tuberculosis strains (MICs = 0.7-1.5 μg/ml), including strains resistant to ethambutol (Item No. 23713), isoniazid (Item No. 20378), rifampicin (Item No. 14423), and rifabutin (Item No. 16468). BM212 also inhibits the growth of M. fortuitum, M. smegmatis, M. kansasii, and M. avium strains (MICs = 3.1-12.5, 3.1-25, 3.1-6.2, and 0.4-3.1 μg/ml, respectively). It inhibits replication of intracellular M. tuberculosis in infected U937 macrophages in a dose-dependent manner at concentrations ranging from 0.5-10 μg/ml. Some M. smegmatis, M. bovis BCG, and M. tuberculosis H37Rv mutant strains carry mutations in the mycobacterium membrane protein large 3 (mmpL3) gene and are resistant to BM212, indicating mmpL3 is likely a cellular target of BM212.2
WARNING This product is not for human or veterinary use.
1. Bactericidal activities of the pyrrole derivative BM212 against multidrug-
2. MmpL3 is the cellular target of the antitubercular pyrrole derivative BM212. Antimicrob. Agents Chemother. 56(1), 324-331 (2012).